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Increased Serum CCL28 Levels in Patients with Atopic Dermatitis,
Psoriasis Vulgaris and Bullous Pemphigoid
To the Editor:
Atopic dermatitis is an inflammatory skin disease that is
characterized by pruritic and eczematous lesions persisting
chronically. Histopathologically, the skin lesions in atopic
dermatitis show infiltration of T lymphocytes, especially cu-
taneous lymphocyte antigen-positive memory T cells, as
well as eosinophils and macrophages (Novak et al, 2003).
Previous studies revealed that increased amounts of thy-
mus and activation-regulated chemokine (CCL17) and cu-
taneous T cell-attracting chemokine (CTACK)/CCL27 were
detected in the serum and lesional keratinocytes of patients
with atopic dermatitis (Kakinuma et al, 2001, 2003). These
results suggest involvement of these chemokines in the
pathogenesis of this disease.
Psoriasis vulgaris is also a chronic and relapsing inflam-
matory skin disease characterized as a T cell-mediated au-
toimmune disorder (Chang, 1992). CTACK/CCL27 was
strongly detected in the serum and lesional keratinocytes
of patients with psoriasis vulgaris (Kakinuma et al, 2003). It
has been proposed that interaction between T cells and
epidermal keratinocytes plays a central role in the patho-
genesis of psoriasis vulgaris (Chang, 1992).
Bullous pemphigoid is a blistering autoimmune skin dis-
ease. It often provokes lesional eosinophil infiltration (Pier-
ard et al, 1961). Eotaxin/CCL11 was strongly detected in
blister fluid of bullous pemphigoid and strongly expressed in
keratinocytes around blisters of this disease (Wakugawa
et al, 2000).
Mucosae-associated epithelial chemokine (MEC)/CCL28
is a novel chemokine ligand for CC chemokine receptor
(CCR) 10 and CCR3 (Pan et al, 2000). MEC/CCL28 is most
homologous to CTACK/CCL27, displaying about 40% iden-
tity, and is most abundant in the salivary gland, with strong
expression in other tissues associated with mucosal epi-
thelial surfaces, including colon, trachea, and mammary
gland. MEC/CCL28 attracts subsets of memory lymph-
ocytes and eosinophils (Pan et al, 2000). Wang et al (2000)
showed that MEC/CCL28 mRNA was expressed predom-
inantly in psoriasis patient skin samples and to a lesser
degree in healthy human skin. But MEC/CCL28 production
at protein levels in skin is totally unknown. Furthermore,
there has been no report of serum MEC/CCL28 levels in
patients with skin diseases. This prompted us to investigate
the relationship between MEC/CCL28 and skin diseases.
Therefore, we examined serum MEC/CCL28 levels of
patients with atopic dermatitis, psoriasis vulgaris, and
bullous pemphigoid. Furthermore, in order to determine
which cells produced MEC/CCL28 in skin, we performed
Figure1
Serum CCL28 levels. Serum mucosae-associated epithelial chemo-
kine (MEC)/CCL28 levels in patients with atopic dermatitis (AD), pso-
riasis vulgaris (PsV), bullous pemphigoid (BP), and healthy controls
(Control). Data are presented as mean  standard error.
Abbreviations: CCR, CC chemokine receptor; CTACK, cutaneous T
cell-attracting chemokine; MEC, Mucosae-associated epithelial
chemokine
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immunohistochemical staining of this chemokine in the les-
ional skin of patients with these diseases.
Forty-eight patients with atopic dermatitis (mean 
standard deviation age: 28.7  6.7 y), 20 patients with
psoriasis vulgaris (28.6  6.3 y), 28 patients with bullous
pemphigoid (68.2  20.1 y), and 20 healthy controls
(28.5  8.4 y) were enrolled in this study. The medical eth-
ical committee of the University of Tokyo approved all de-
scribed studies and the study was conducted according to
Declaration of Helsinki Principles. Informed consent was
obtained to use the sera and skin tissues from the patients
and healthy controls. The 20 healthy controls had no history
of allergy, psoriasis or bullous disease. All sera were stored
at 201C until use. ELISA was performed using MEC/
CCL28 immunoassay kits obtained from R&D Systems
(Minneapolis, Minnesota). Serum levels of MEC/CCL28
were measured according to the manufacturer’s instruc-
tions. Optical densities were measured at 450 nm with a
Bio-Rad Model 550 microplate reader (Bio-Rad Laborato-
ries, Hercules, California). The concentrations were calcu-
lated from the standard curve generated by a curve-fitting
program. Data obtained from the ELISA are presented as
mean  standard error. Data were analyzed using Mann–
Whitney’s U test and paired t test. A p-value less than 0.05
was considered to be statistically significant.
Biopsy specimens obtained from patients and healthy
controls were used for immunohistochemical staining. To
detect MEC/CCL28, affinity-purified goat polyclonal anti-
human MEC/CCL28 (Dako Cytomation, Glostrup, Denmark)
was used. Normal goat IgG1 (Santa Cruz Biotechnology,
Santa Cruz, California) was used as an isotype-matched
control.
The serum MEC/CCL28 levels of patients with atopic
dermatitis (148.9  13.6 pg per mL), psoriasis vulgaris
(167.8  34.2 pg per mL), and bullous pemphigoid
(89.2  45.3 pg per mL) were significantly higher than those
in healthy controls (44.7  5.9 pg per mL) (Fig 1). Because
patients with bullous pemphigoid were much older than the
other cohorts, it will be necessary to compare them with
much older healthy controls in a future study in order to
confirm the conclusion. The serum MEC/CCL28 levels did
not correlate with disease activity of these three conditions
(data not shown). The elevated serum MEC/CCL28 levels of
patients with atopic dermatitis tended to decrease after
treatments (n¼6, before: 169.8  75.9 pg per mL, after:
65.8  22.7 pg per mL), although the change was not sig-
nificant (data not shown).
MEC/CCL28 was strongly expressed in epidermal kera-
tinocytes of patients with atopic dermatitis and psoriasis
vulgaris, and weakly expressed in epidermal keratinocytes
of patients with bullous pemphigoid, insect bite, healthy
controls, and non-lesional skin of patients with psoriasis
vulgaris (Fig 2). Thus, MEC/CCL28 was strongly expressed
only in the lesional skin of systemic skin diseases, such as
atopic dermatitis and psoriasis vulgaris.
This is the first report describing MEC/CCL28 expression
by epidermal keratinocytes in skin and elevated levels of
this chemokine in the serum of patients with some inflam-
matory skin diseases.
Both CTACK/CCL27 and MEC/CCL28 attract CCR10þ
lymphocytes. The CCR10þ lymphocytes invading the skin
in atopic dermatitis and psoriasis have different Th1/Th2
profiles (Vestergaard et al, 2000). Therefore, CTACK/CCL27
and MEC/CCL28 may contribute to the pathogenesis of
both a Th2-dominant disease like atopic dermatitis and a
Th1-dominant disease like psoriasis vulgaris.
MEC/CCL28, but not CTACK/CCL27, stimulates migra-
tion of CCR3 transfectants as well as eosinophils (Pan et al,
2000). In this context, MEC/CCL28 may play a role, in con-
junction with other regulatory elements, in the recruitment of
eosinophils and potentially, of rare CCR3þ T cells into epi-
dermis. MEC/CCL28 seems to be one of the important
chemokines in the lesional formation of eosinophil infiltrat-
ing diseases like atopic dermatitis and bullous pemphigoid.
These results suggest that MEC/CCL28 is involved in the
pathogenesis of these choronic inflammatory skin diseases
in cooperation with other chemokines.
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Figure 2
Expression of CCL28 in the epidermis.
Mucosae-associated epithelial chemo-
kine (CCL28) was strongly expressed in
the lesional epidermal keratinocytes of
patients with atopic dermatitis (a) and
psoriasis vulgaris (b). It was weakly ex-
pressed in patients with bullous pe-
mphigoid (c) and healthy controls (d). It
was hardly expressed in patients with in-
sect bite (e) and non-lesional skin of pa-
tients with psoriasis vulgaris (f). When an
isotype-matched control was used, no
reactivity was observed in patients with
atopic dermatitis (g) (scale bar¼ 200 mm).
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Cultured Cells from the Adult Human Hair Follicle
Dermis can be Directed Toward Adipogenic and
Osteogenic Differentiation
To The Editor:
Mounting evidence suggests that adult stem cells have
greater plasticity than previously thought. Among stem cells
derived from mesenchymal tissues (e.g., Toma et al, 2001;
Zuk et al, 2001; Jiang et al, 2002), one population from the
skin dermis has received considerable prominence, owing
to its accessibility and wide spectrum of differentiation ac-
tivities in culture (Toma et al, 2001).
Within the adult hair follicle dermis, two developmentally
active cell populations, the dermal papilla (DP) and dermal
sheath (DS), have well-established instructive powers in re-
lation to the control of hair follicle cycling and induction.
Although the stem cell activity of the hair follicle epithelium
has been studied intensively (Taylor et al, 2000; Morris et al,
2004; Tumbar et al, 2004), until recently the follicle dermis
has been largely overlooked in this context.
We have previously suggested that follicle dermal cells
have extensive stem or progenitor cell activities within the
skin, including an important role in wound healing (Jahoda
and Reynolds, 2001). Using rodent models we have dem-
onstrated that the follicle dermis harbors hematopoietic
stem cell activity (Lako et al, 2002). We recently directed
clonally derived papilla and sheath cell lines towards ad-
ipocyte and osteocyte phenotypes (Jahoda et al, 2003). For
follicle dermal stem cells to be useful in any therapeutic
context, we need, however, to show that human hair follicle
dermal stem cells have similar capabilities. Here, we report
adipogenic and osteogenic differentiation in human hair
follicle-derived DP and DS cultures. Human scalp or beard
follicles were isolated from skin biopsies from four individ-
uals (aged 23,48, 89, and 91 y). DP and DS tissues were
dissected from amputated end bulbs as previously de-
scribed (Reynolds et al, 1999). Briefly, amputated follicle
end bulbs were inverted, and the exposed epithelial matrix
was detached. Adherent epithelial cells and debris were
removed, the DP and DS were separated and explant cul-
tures initiated in MEM plus 20% FBS from a minimum of 10
isolated DP or DS samples from each biopsy.
Cells between passage 3 and 7 (50,000 cells per 35 mm
plate) were allowed to adhere overnight in MEM plus 10%
FBS at 371C and 5% CO2. In control dishes, cells were kept
in this medium. Others were incubated in either osteogenic
media (MEM plus 10% FBS, 100 nM dexamethasone, 10 mM
b-glycerophosphate, supplemented every 3 d with 50 mM
L-ascorbate-2-phosphate) or adipogenic medium (MEM
plus 15% rabbit serum, 2.07 mM insulin, 100 nM dexa-
methasone, supplemented with 9 mM isobutyl-methylxan-
thine after 9 d of culture) (both modified from Zuk et al,
2001). Cultures were maintained for 6–11 d and medium
changed every 3–4 days.
For each of the osteogenic and adipogenic differenti-
ation experiments, the DP and DS cell lines were estab-
lished from two different human samples. All established
cell lines could be directed towards osteogenesis (five of
five) and, in contrast to a previous report (Iguchi et al,
2001), adipogenesis (five of five). These differentiation
events occured irrespective of the origin of the cell line or
patient age. Interestingly, as repeat experiments wereAbbreviations: DP, dermal papilla; DS, dermal sheath
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